Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Relationship between clinical findings of patients with bullous pemphigoid and antigens recognized by their circulating antibasement membrane zone antibodies].
Gary A, Carvalho P, Louison JB, Helot MF, Gilbert D, Bernard P, Roujeau JC, Bedane C, Delaporte E, Vaillant L, Dreno B, Saiag P, Tancrede-Bohin E, Plantin P, D'Incan M, Sassolas B, Lok C, Labeille B, Pauwels C, Chosidow O, Picard C, Loche F, Guillaume JC, Joly P. Gary A, et al. Ann Dermatol Venereol. 2004 Apr;131(4):333-7. doi: 10.1016/s0151-9638(04)93611-3. Ann Dermatol Venereol. 2004. PMID: 15258506 French.
Hypersensitivity syndrome associated with zalcitabine therapy.
Tancrède-Bohin E, Grange F, Bournerias I, Roujeau JC, Guillaume JC. Tancrède-Bohin E, et al. Lancet. 1996 Apr 6;347(9006):971. doi: 10.1016/s0140-6736(96)91459-2. Lancet. 1996. PMID: 8598782 No abstract available.
Clinical criteria for the diagnosis of bullous pemphigoid: a reevaluation according to immunoblot analysis of patient sera.
Joly P, Courville P, Lok C, Bernard P, Saiag P, Dreno B, Delaporte E, Bedane C, Picard C, Sassolas B, Plantin P, D'Incan M, Chosidow O, Pauwels C, Lambert D, Loche F, Prost C, Tancrede-Bohin E, Guillaume JC, Roujeau JC, Gilbert D, Tron F, Vaillant L; French Bullous Study Group. Joly P, et al. Dermatology. 2004;208(1):16-20. doi: 10.1159/000075040. Dermatology. 2004. PMID: 14730231
[Bullous pemphigoid in young patients: a retrospective study of 74 cases].
Bourdon-Lanoy E, Roujeau JC, Joly P, Guillaume JC, Bernard P, Prost C, Tancrède-Bohin E, Delaporte E, Picard-Dahan C, Albes B, Bedane C, Doutre MS, Chosidow O, Lok C, Pauwels C, Chevrand-Breton J, Sassolas B, Richard MA. Bourdon-Lanoy E, et al. Ann Dermatol Venereol. 2005 Feb;132(2):115-22. doi: 10.1016/s0151-9638(05)79220-6. Ann Dermatol Venereol. 2005. PMID: 15798559 French.
Prediction of survival for patients with bullous pemphigoid: a prospective study.
Joly P, Benichou J, Lok C, Hellot MF, Saiag P, Tancrede-Bohin E, Sassolas B, Labeille B, Doutre MS, Gorin I, Pauwels C, Chosidow O, Caux F, Estève E, Dutronc Y, Sigal M, Prost C, Maillard H, Guillaume JC, Roujeau JC. Joly P, et al. Arch Dermatol. 2005 Jun;141(6):691-8. doi: 10.1001/archderm.141.6.691. Arch Dermatol. 2005. PMID: 15967914 Clinical Trial.
A single cycle of rituximab for the treatment of severe pemphigus.
Joly P, Mouquet H, Roujeau JC, D'Incan M, Gilbert D, Jacquot S, Gougeon ML, Bedane C, Muller R, Dreno B, Doutre MS, Delaporte E, Pauwels C, Franck N, Caux F, Picard C, Tancrede-Bohin E, Bernard P, Tron F, Hertl M, Musette P. Joly P, et al. N Engl J Med. 2007 Aug 9;357(6):545-52. doi: 10.1056/NEJMoa067752. N Engl J Med. 2007. PMID: 17687130 Free article. Clinical Trial.
A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study.
Joly P, Roujeau JC, Benichou J, Delaporte E, D'Incan M, Dreno B, Bedane C, Sparsa A, Gorin I, Picard C, Tancrede-Bohin E, Sassolas B, Lok C, Guillaume JC, Doutre MS, Richard MA, Caux F, Prost C, Plantin P, Chosidow O, Pauwels C, Maillard H, Saiag P, Descamps V, Chevrant-Breton J, Dereure O, Hellot MF, Esteve E, Bernard P. Joly P, et al. J Invest Dermatol. 2009 Jul;129(7):1681-7. doi: 10.1038/jid.2008.412. Epub 2009 Jan 29. J Invest Dermatol. 2009. PMID: 19177141 Free article. Clinical Trial.
Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response.
Colliou N, Picard D, Caillot F, Calbo S, Le Corre S, Lim A, Lemercier B, Le Mauff B, Maho-Vaillant M, Jacquot S, Bedane C, Bernard P, Caux F, Prost C, Delaporte E, Doutre MS, Dreno B, Franck N, Ingen-Housz-Oro S, Chosidow O, Pauwels C, Picard C, Roujeau JC, Sigal M, Tancrede-Bohin E, Templier I, Eming R, Hertl M, D'Incan M, Joly P, Musette P. Colliou N, et al. Sci Transl Med. 2013 Mar 6;5(175):175ra30. doi: 10.1126/scitranslmed.3005166. Sci Transl Med. 2013. PMID: 23467561
Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus.
Boulard C, Duvert Lehembre S, Picard-Dahan C, Kern JS, Zambruno G, Feliciani C, Marinovic B, Vabres P, Borradori L, Prost-Squarcioni C, Labeille B, Richard MA, Ingen-Housz-Oro S, Houivet E, Werth VP, Murrell DF, Hertl M, Benichou J, Joly P; International Pemphigus Study Group. Boulard C, et al. Br J Dermatol. 2016 Jul;175(1):142-9. doi: 10.1111/bjd.14405. Epub 2016 Apr 3. Br J Dermatol. 2016. PMID: 26800395 Free article.
34 results